hVIVO sees uptick in human challenge trial demand - ICYMI

hVIVO PLC (AIM:HVO) chief executive, Yamin ‘Mo' Khan, talked with Proactive about the company's latest contract win with a new European biotech client for an influenza human challenge trial. Khan explained that the trial is set to begin almost immediately, with most of the revenue expected to be recognised in 2026 and additional contributions extending into 2027.